Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine

Nature Biotechnology

Volumn 20, Issue 1, 2002, Pages 64-69

  Kumamoto, Tadashi ^a   Huang, Eric K ^b   Paek, Hyun Joon ^b   Morita, Akimichi ^b   Matsue, Hiroyuki ^a   Valentini, Robert F ^c   Takashima, Akira ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CELLS; IMMUNIZATION; ORGANIC POLYMERS; PROTEINS; TUMORS;

LYMPH NODES;

VACCINES;

ETHYLENE VINYL ACETATE COPOLYMER; HAPTEN; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNIZATION; CHEMOTAXIS; CONTROLLED STUDY; COST CONTROL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG COST; EPIDERMIS; LANGERHANS CELL; LEUKOCYTE MIGRATION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR IMMUNITY;

ANIMALS; BIOTECHNOLOGY; BONE MARROW CELLS; CANCER VACCINES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES, CC; CHEMOTAXIS; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMIS; ISLETS OF LANGERHANS; LIGANDS; LYMPH NODES; MICE; MICE, INBRED BALB C; POLYMERS; POLYVINYLS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

ANIMALIA;

EID: 0036139893     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0102-64     Document Type: Article

References (52)

1. Dendritic cells and the control of immunity
2. Immunobiology of dendritic cells
3. Dendritic cells in cancer immunotherapy
4. The dendritic cell and human cancer vaccines
5. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
6. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
7. Tumor antigen presentation by murine epidermal cells
8. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
9. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
10. Peptide- pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
11. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
12. + T cells for efficient tumor cell lysis
13. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
14. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
15. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
16. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
17. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
18. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
19. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
20. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
21. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
22. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
23. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
24. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
25. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs
26. The role of chemokine receptors in primary, effector, and memory immune responses
27. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sties
28. Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties
29. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is upregulated upon maturation
30. Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes
31. Distribution of immunogenic cells after painting with the contact sensitizers fluorescein isothiocyanate and oxazolone. Different sensitizers form immunogenic complexes with different cell populations
32. Dendritic epidermal T cells inhibit T cell proliferation and may induce tolerance by cytotoxicity
33. Induction of antitumor immunity using bone marrow-generated dendritic cells
34. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
35. Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine
36. DNA immunization induces protective immunity against B-cell lymphoma
37. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity
38. Dendritic cell therapy of cancer and HIV infection
39. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth
40. Macrophage inflammatory protein 3α is involved in the constitutive trafficking of epidermal Langerhans cells
41. Macrophage inflammatory protein 3α is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors
42. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo
43. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
44. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells
45. Feasibility of CTLA41g gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro
46. + T cells
47. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
48. Human osteoblast response in vitro to platelet-derived growth factor and transforming growth factor-beta delivered from controlled-release polymer rods
49. Controlled and modulated release of basic fibroblast growth factor
50. Dendritic cells produce macrophage inflammatory protein-1γ, a new member of the CC chemokine family
51. Development of a peptide inhibitor or hyaluronan-mediated leukocyte trafficking
52. Killing of skin-derived tumor cells by mouse dendritic epidermal T cells